Drug intelligence / Profile preview

multiPlus

Development stage: Unknown
Lead developer: Fresenius Medical Care
Administration: Extracorporeal

Overview

multiPlus is a phosphate-containing dialysis solution developed by Fresenius Medical Care Deutschland GmbH for use in continuous renal replacement therapy (CRRT) in patients with acute kidney injury (AKI). It is specifically designed for use with the multiFiltrate PRO System during continuous veno-venous hemodialysis (CVVHD) or hemodiafiltration (CVVHDF). The solution functions by facilitating the removal of metabolic waste products, such as serum creatinine and uremic toxins, while providing supplemental phosphate to prevent hypophosphatemia, a common complication of CRRT. In 2020, the FDA granted Emergency Use Authorization (EUA) for multiPlus to support the treatment of AKI during the COVID-19 pandemic.

Brand names: multiPlus
Other names: multiPlus dialysatemultiPlus dialysis solution

Beyond the preview

Go deeper on multiPlus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on multiPlus.

Explore the full profile